Business Wire

nShift: Retailers urged to integrate customer data as 84% of execs struggle with data silos

4.9.2024 16:49:00 CEST | Business Wire | Press release

Share

New nShift guide draws attention to untapped data within delivery and post-purchase processes

Disparate data could be causing retailers to miss crucial commercial opportunities as 84% of execs confess that they have felt the effects of “data silos”.1 This is causing them to miss out on crucial data from the delivery process which often sits across different systems and multiple businesses.

In a new report, nShift, the global leader in experience and delivery management (DMXM) is encouraging retailers to make the most of data generated during the delivery and post-purchase experience.

Retailers have increasingly used large data collections to help improve their sales and operations. A new report by nShift, “Creating a data-driven delivery experience” argues that too often, retailers are missing crucial insights from the delivery and post-purchase process. Typically, such data sits in silos across the organization – or with external carrier companies - making it difficult to use effectively.

Sean Sherwin-Smith, post-purchase product director at nShift said: “The delivery process is a fantastic example of where retailers sit upon a wealth of untapped data. Information from the delivery and post-purchase process can shine a real light on how retailers and warehouses can improve efficiency, revamp the customer experience and turn one-off purchases into lifelong customer relationships.

“The problem is that retailers tend to view the fulfillment process and the customer experience as two separate things. As a result, data sits in disjointed systems and is rarely compiled and analyzed. Only by bringing deliveries and experience management together can retailers tap into crucial insights and create data-driven growth strategies.”

The new nShift report explores how leveraging data from the delivery and post-purchase experience can help retailers:

  1. Optimize and reduce carrier costs - the greater access a retailer or warehouse has to carrier costs and performance data, the more easily they can select the most cost-effective last-mile delivery option for each shipment
  2. Improve conversions at checkout – by ensuring that a shopper sees the delivery option they want at the top of the list of choices
  3. Create better customer communications – retailers can then create relevant communications to match how often, according to data, people are checking updates and weave in product plugs or brand messages as appropriate
  4. Increase customer loyalty by keeping their delivery promise – comparing performance data across carrier companies enables retailers to drive up standards and negotiate better results
  5. Retain more revenue by reducing volumes – by paying close attention to what issues are causing people to send products back and addressing such issues with product and marketing teams
  6. Influence consumer behavior – to encourage more shoppers into physical stores or to alter their returns habits

nShift’s DMXM suits of solutions bring together core components of delivery management (such as label printing and carrier booking) with cutting-edge consumer applications. Because delivery management, order tracking, checkout and returns all sit on one platform, it’s easy to join up the relevant data. A range of easy-to-use dashboards makes insights clear, digestible, sharable and actionable.

Read the full report: “Creating a data-driven delivery experience: how delivery and experience management (DMXM) unlocks business-changing insights for online retailers

About nShift

nShift’s delivery & experience management (DMXM) platform drives ecommerce success. Grow beyond limits with constant innovation and the world’s largest carrier network. Build customer loyalty with end-to-end tools that enhance experience. Unify data into usable insight that connects and optimizes processes. With nShift, make delivery the essential link between your brand and your customers.

nShift. Worry less. Ship smarter. www.nshift.com

1https://www.mckinsey.com/capabilities/growth-marketing-and-sales/our-insights/the-value-of-getting-personalization-right-or-wrong-is-multiplying

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904597279/en/

Contacts

James Ellerington: James.Ellerington@fourteenforty.uk / (+44) 07725 534941

James Ellerington: James.Ellerington@fourteenforty.uk / (+44) 07725 534941

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye